Background
Treatment of metastatic Ewing sarcoma (ES) remains an unsolved clinical problem, with a 3-year event free survival at 27% for patients with metastases at diagnosis. Tumor hypoxia is one of the few known metastatic factors in ES, yet the exact pathways underlying its actions remain unknown.
